Orphan disease biotech GlycoMimetics files for a $86 million IPO
GlycoMimetics, a clinical-stage biotech developing treatments for orphan diseases, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Gaithersburg, MD-based company, which was founded in 2003 and booked $12 million in collaboration and grant revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol GLYC. GlycoMimetics initially filed confidentially on August 21, 2013. Jefferies and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.